Dupilumab Use Is Associated With Protection From Coronavirus Disease 2019 Mortality: A Retrospective Analysis

Safety and Efficacy of Dupilumab for the Treatment of Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019: A Phase 2a Trial

(2022) Jennifer Sasson et al.   Open Forum Infectious Diseases

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

(2021) Obbina Abani et al.   LANCET

COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab

(2021) Benjamin Ungar et al.   Journal of Allergy and Clinical Immunology-In Practice

Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report

(2020)   NEW ENGLAND JOURNAL OF MEDICINE

Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma

(2018) Mario Castro et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis

(2014) Lisa A. Beck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dupilumab in Persistent Asthma with Elevated Eosinophil Levels

(2013) Sally Wenzel et al.   NEW ENGLAND JOURNAL OF MEDICINE